|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Anexo 1. Características de estudios incluidos y evaluación de calidad de evidencia según GRADE. (Tratamiento farmacológico) Autor, Año de publicación, Diseño** | **N, Número de estudios** | | | **Tratamiento** | | | **Resultados: Eficacia (1)** | | **Resultados: Eficacia (2)** | | | **Resultados: Seguridad** | | | **Calidad de la evidencia (GRADE)/**  **Nivel de la evidencia OCEBM** |
| Wang,2018  MA | | | 3220,2 | | | **Adalimumab:** 40mg Q2W **Certolizumab:** 200mg Q2W, 400mg Q4W **Etanercept:** 25mg BIW,, 50mg QW **Golimumab:** 50mg Q4W,100mg Q4W **Infliximab:** 5mg/kg,3mg/kg **Infliximab-dyyb:** 5mg/kg  Comparador: Placebo | | | | **Adalimumab:** - BASDAI (MD -1.72; ICr95% -2.56,-0.68)\* - BASFI (MD -1.67; ICr95% -2.94,-0.35)\* - PCR (MD -1.31; ICr95% -2.04,-0.73)\* **Certolizumab:** - BASDAI (MD -1.81; ICr95% -2.83,-0.76)\* - BASFI (MD -1.40; ICr95% -2.72,-0.09)\* - PCR (MD -0.70; ICr95% -1.46,0.07) **Etanercept:** - BASDAI (MD -1.91; ICr95% -3.26,-0.56)\* - BASFI (MD -1.42; ICr95% -3.19,0.33) - PCR (MD -1.19; ICr95% -2.08,-0.33)\* **Golimumab:** - BASDAI (MD -1.48; ICr95% -2.41,-0.40)\* - BASFI (MD -1.32; ICr95% -2.24,-0.46)\* - PCR (MD -1.08; ICr95% -1.59,-0.62)\* **Infliximab:** - BASDAI (MD -2.18; ICr95% -3.04,-0.83)\* - BASFI (MD -1.45; ICr95% -2.74,-0.13)\* - PCR (MD -1.22; ICr95% -1.98,-0.61)\* **Infliximab-dyyb:** - BASDAI (MD -2.79; ICr95% -4.26,-0.77)\* - BASFI (MD -1.86; ICr95% -4.02,-0.36)\* - PCR (MD -1.14; ICr95% -2.44,0.08)\* | | | Alta/  1a | | |
| Wang,2017  MA | | | 2403,25 | | | **Adalimumab:** 40mg Q2W **Certolizumab:** 200mg Q2W **Etanercept:** 25mg BIW, 50mg QW **Golimumab:** 50mg Q4W, 100mg Q4W **Infliximab:** 5mg/kg **Sarilumab:** 100-200mg Q2W **Secukinumab:** 2x10mg/kg día 1 y día 22 **Tocilizumab:** 8mg/kg Q4W  Comparador: Placebo | | | | **Adalimumab:** RIS (IS 1.25; IC95% 0.11,13,89) **Certolizumab:** RIS (IS 2.48; IC95% 0.12,52.17) **Etanercept:** EAS (IS 0.54; IC95% 0.10,2.95) **Golimumab:** EAS (IS 1.43; IC95% 0.15,13.80) **Infliximab:** EAS (IS 4.77; IC95% 0.26,88.97) **No FNT:** EAS (IS 2.33; IC95% 0.12,45.40) | | | Moderada/  1a (-) | | |
| Hou,2017  MA | | | 2032,14 | | | **Adalimumab:** 40mg Q2W **Etanercept:** 25mg BIW, 50mg QW **Golimumab:** 50mg Q4W,100mg Q4W **Infliximab:** 5mg/kg  Comparador: Placebo | | | | **Todos:** - EAS (OR 1.34; IC95% 0.87,2.05) - INFECCION (OR 1.59; IC95% 0.63,4.01) - ABANDONO (OR 1.55; IC95% 0.95,2.54) - MALIGNIDAD (OR 0.98; IC95% 0.25,3.85) **Adalimumab:** - EAS (NC 0.89; IC95% 0.26,3.10) - INFECCION (NC 0.51; IC95% 0.07,3.63) - ABANDONO (NC 1.96; IC95% 0.48,7.99) **Etanercept:** - EAS (NC 1.37; IC95% 0.73,2.59) - INFECCION (NC 1.48; IC95%0.22,10.11) - ABANDONO (NC 1.32; IC95% 0.72,2.44) **Golimumab:** - EAS (NC 1.24; IC95% 0.59,2.61) - INFECCION (NC 2.58; IC95%0.47,14.16) - ABANDONO (NC 1.88; IC95%0.50,7.17) **Infliximab:** - EAS (NC 2.27; IC95% 0.58,8.94) - INFECCION (NC 2.45; IC95% 0.26,22.84) - ABANDONO (NC 2.46; IC95% 0.42,14.29) **Dosis alta vs dosis normal:** - EAS (OR 1.43; IC95% 0.61,3.38) - INFECCION (OR 1.26; IC95% 0.28,5.63) - ABANDONO (OR 2.70; IC95% 0.70,10.47) | | | Baja/  1a (-) | | |
| Liu,2016  MA | | 2574,16 | | | **Golimumab:** 50mg Q4W **Etanercept:** 25mg BIW, 50mg QW | | | **Golimumab vs placebo:** - ASAS20 (OR 3.82; IC95% 2.49,5.87)\* | | | **Golimumab vs placebo:** - EAS (OR 0.70; IC95% 0.18,2.67) | | | Alta/  1a | |